Cyclic Dinucleotide PRR Agonists for Genotype-Agnostic Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapies face challenges such as the emergence of drug-resistant variants, long-term treatment requirements, and side effects, as well as limitations in effectiveness across different viral genotypes.
Innovation Solution
The development of cyclic dinucleotide compounds that activate pattern recognition receptors (PRRs) in the host, inducing an immune response and potentially treating microbial infections and proliferative diseases like cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiviral therapies are used, then viral infection treatment is achieved, but drug-resistant variants emerge and long-term treatment is required
Solution Approach 1:
The patent applies preliminary action by using PRR agonists to preemptively activate the host's innate immune system before viral infection establishes full control. This approach prime's the immune system to recognize and respond to viral patterns more effectively, potentially reducing the need for long-term antiviral therapy while maintaining treatment effectiveness.
Solution Approach 2:
The patent employs self-service by stimulating the host's own immune system through PRR activation. Instead of relying solely on external antiviral drugs, the therapy triggers the body's intrinsic immune defenses to combat viral infections, which may reduce dependency on prolonged pharmacological treatment and minimize the development of drug resistance.
2Reliability
If current antiviral therapies are used, then viral infection is treated, but unwanted side effects and risk of relapse occur
Solution Approach 1:
The patent converts the harmful effect of viral infection into a beneficial immune response by using PRR agonists to trigger controlled activation of the innate immune system. This approach transforms the threat of viral infection into an opportunity to enhance host defense mechanisms, potentially reducing side effects and relapse risks associated with conventional antiviral therapies.
Solution Approach 2:
The patent applies parameter changes by modulating the activation state and intensity of pattern recognition receptors to achieve optimal immune response. By carefully controlling the parameters of PRR activation, the therapy aims to maximize antiviral effectiveness while minimizing harmful side effects and relapse risks compared to traditional antiviral treatments.
3Reliability
If drugs are developed against one viral genotype, then that genotype is treated effectively, but other genotypes are not affected
Solution Approach 1:
The patent applies universality by developing PRR agonists that can recognize and activate pattern recognition receptors common to multiple viral genotypes. Since PRRs are conserved across different viral families and genotypes, this approach creates a universal therapeutic mechanism that can effectively treat various viral infections without requiring genotype-specific drugs, thereby enhancing cross-genotype effectiveness.
4Adaptability or versatility
If small molecule mimics of viral-derived RNA are used, then genotype-agnostic treatment is achieved, but the mechanism of action must be carefully controlled
Solution Approach 1:
The patent uses PRR agonists as intermediary molecules that bridge the gap between viral infection and host immune response. These agonists act as mediators that trigger controlled activation of pattern recognition receptors, enabling genotype-agnostic treatment while providing a manageable mechanism of action through well-characterized immune signaling pathways.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds can induce the expression of PRRs, such as STING and RIG-I, triggering an immune response that is agnostic to viral genotype, potentially limiting drug resistance and toxicity, and showing promise in both antiviral and immunotherapy applications.
Implementation Method 1
The recognition and elimination of foreign substances occurs through host recognition of evolutionarily conserved microbial structures known as pathogen-associated molecular patterns (PAMPs). Host recognition may occur by multiple pathways, such as activation of pattern recognition receptors (PRRs).
Implementation Method 2
Stimulator of interferon genes (STING) is a cytoplasmic adaptor protein that activates the TBK1-IRF3 signaling complex, resulting in induction of type I interferons (IFN-β and IFN-α) and other immune pathway proteins.
Data Source
AI summary
Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.